{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:27:37Z","timestamp":1793406457102,"version":"4.5.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005918","name":"Christian Medical College, Vellore","doi-asserted-by":"publisher","award":["0,424,159"],"award-info":[{"award-number":["0,424,159"]}],"id":[{"id":"10.13039\/501100005918","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jgar.2025.07.009","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T20:40:33Z","timestamp":1752612033000},"page":"464-469","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Successful use of cefepime\/zidebactam in deep-seated infections due to extensively drug-resistant Pseudomonas aeruginosa: A case series"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2175-6886","authenticated-orcid":false,"given":"Pooja","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5891-8542","authenticated-orcid":false,"given":"Ayyanraj","family":"Neeravi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Karthik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christy Merin","family":"Mathew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Hephzibah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna Elizabeth","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balaji","family":"Veeraraghavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abi","family":"Manesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10459","key":"10.1016\/j.jgar.2025.07.009_bib0001","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S0140-6736(24)01867-1","article-title":"Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050","volume":"404","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jgar.2025.07.009_bib0002","unstructured":"WHO bacterial priority pathogens list, 2024: bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. [cited 2024 Jun 2]. Available from: https:\/\/www.who.int\/publications-detail-redirect\/9789240093461."},{"issue":"6","key":"10.1016\/j.jgar.2025.07.009_bib0003","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/QCO.0000000000000966","article-title":"MDR\/XDR\/PDR or DTR? Which definition best fits the resistance profile of Pseudomonas aeruginosa?","volume":"36","author":"Cosentino","year":"2023","journal-title":"Curr Opin Infect Dis"},{"issue":"1","key":"10.1016\/j.jgar.2025.07.009_bib0004","doi-asserted-by":"crossref","first-page":"e00115","DOI":"10.1128\/CMR.00115-20","article-title":"New \u03b2-lactam-\u03b2-lactamase inhibitor combinations","volume":"34","author":"Yahav","year":"2020","journal-title":"Clin Microbiol Rev"},{"issue":"12","key":"10.1016\/j.jgar.2025.07.009_bib0005","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01648-19","article-title":"WCK 5222 (Cefepime-Zidebactam) pharmacodynamic target analysis against metallo-\u03b2-lactamase-producing Enterobacteriaceae in the neutropenic mouse pneumonia model","volume":"63","author":"Lepak","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.jgar.2025.07.009_bib0006","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00500-23","article-title":"Successful use of Cefepime-Zidebactam (WCK 5222) as a salvage therapy for the treatment of disseminated extensively drug-resistant New Delhi metallo-\u03b2-lactamase-producing Pseudomonas aeruginosa infection in an adult patient with acute T-cell leukemia","volume":"67","author":"Tirlangi","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.07.009_bib0007","doi-asserted-by":"crossref","DOI":"10.1007\/s10096-024-04791-1","article-title":"Successful treatment of sino-pulmonary infection & skull base osteomyelitis caused by New Delhi metallo-\u03b2-lactamase-producing Pseudomonas aeruginosa in a renal transplant recipient by using an investigational antibiotic cefepime\/zidebactam (WCK 5222)","author":"Soman","year":"2024","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"1","key":"10.1016\/j.jgar.2025.07.009_bib0008","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12941-023-00606-x","volume":"22","author":"Dubey","year":"2023","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"9","key":"10.1016\/j.jgar.2025.07.009_bib0009","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1093\/trstmh\/trae049","article-title":"Difficult to treat Pseudomonas: successful salvage therapy with cefepime-zidebactam","volume":"118","author":"Sebastian","year":"2024","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.jgar.2025.07.009_bib0010","series-title":"Performance standards for antimicrobial susceptibility testing","year":"2024"},{"issue":"7","key":"10.1016\/j.jgar.2025.07.009_bib0011","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1093\/cid\/ciaa1478","volume":"72","author":"Tamma","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.jgar.2025.07.009_bib0012","doi-asserted-by":"crossref","first-page":"e02000","DOI":"10.1128\/AAC.02000-21","article-title":"Geographic patterns of carbapenem-resistant Pseudomonas aeruginosa in the Asia-Pacific Region: results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) Program, 2015\u20132019","volume":"66","author":"Lee","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.jgar.2025.07.009_bib0013","doi-asserted-by":"crossref","first-page":"723","DOI":"10.3390\/antibiotics11060723","article-title":"Cefiderocol: systematic review of mechanisms of resistance, heteroresistance and In vivo emergence of resistance","volume":"11","author":"Karakonstantis","year":"2022","journal-title":"Antibiotics"},{"key":"10.1016\/j.jgar.2025.07.009_bib0014","unstructured":"Wockhardt Ltd; A randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and pharmacokinetics of multiple escalating doses of intravenous zidebactam in healthy adult Human subjects; ClinicalTrials.gov identifier: NCT02674347; Updated : 2016; Accessed 02.10.24: https:\/\/clinicaltrials.gov\/study\/NCT02674347?term=NCT02674347&rank=1."},{"key":"10.1016\/j.jgar.2025.07.009_bib0015","unstructured":"Wockhardt Ltd; A randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and pharmacokinetics of multiple escalating doses of intravenous WCK 5222 (Zidebactam and Cefepime) in Healthy adult human subjects; clinicaltrials.gov identifier: NCT02707107; 2016; Accessed 02.10.24 https:\/\/clinicaltrials.gov\/study\/NCT02707107?term=NCT02707107&rank=1."},{"key":"10.1016\/j.jgar.2025.07.009_bib0016","unstructured":"Wockhardt Ltd; A randomized, double-blind, double-dummy, placebo- and positive-controlled, crossover study to evaluate the effect of WCK 5222 on the QT\/QTc interval in healthy volunteers; ClinicalTrials.gov Identifier: NCT03554304; 2018; Accessed 02.10.24: https:\/\/clinicaltrials.gov\/study\/NCT03554304?term=NCT03554304&rank=1."},{"key":"10.1016\/j.jgar.2025.07.009_bib0017","unstructured":"Wockhardt Ltd; A phase 1, open-label, single-dose study to investigate the pharmacokinetics of intravenous WCK 5222 (FEP-ZID) in patients with renal impairment; ClinicalTrials.gov Identifier : NCT02942810; 2018; Accessed 02.10.24; https:\/\/clinicaltrials.gov\/study\/NCT02942810?intr=FEP-ZID&rank=3."},{"key":"10.1016\/j.jgar.2025.07.009_bib0018","unstructured":"Wockhardt Ltd; A phase 3, randomized, double-blind, multicenter, comparative study to determine the efficacy and safety of Cefepime-zidebactam vs. Meropenem in the treatment of complicated urinary tract infection or acute pyelonephritis in adults; ClinicalTrials.gov Identifier: NCT04979806; 2024; Accessed 02.10.24 https:\/\/clinicaltrials.gov\/study\/NCT04979806?term=NCT04979806&rank=1."},{"key":"10.1016\/j.jgar.2025.07.009_bib0019","unstructured":"S Palwe, P Joshi, H Periasamy and S Bhagwat; Biofilm eradication activity of Zidebactam\/Cefepime (WCK 5222, ZAYNICH), Assessed against Multi-Drug Resistant (MDR) Pseudomonas aeruginosa (PSA) Biofilms; CIDSCON (Conference of Clinical Infectious Diseases Society), August 15th to 18th 2024, Hyderabad, India."}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221371652500164X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221371652500164X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T07:16:54Z","timestamp":1777101414000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221371652500164X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":19,"alternative-id":["S221371652500164X"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2025.07.009","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Successful use of cefepime\/zidebactam in deep-seated infections due to extensively drug-resistant Pseudomonas aeruginosa: A case series","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2025.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}